The company’s sales for the period under review was ₹5,562 crore, up 13.6 per cent from ₹4,895 crore in the same period last year.
| Photo Credit:
DANISH SIDDIQUI
Drugmaker Lupin posted a 113 per cent growth in its profit after tax (PAT) at ₹782 crore, for the three months ended March 31, 2025, as compared to ₹368 crore on the same period last year.
The company’s sales for the period under review was ₹5,562 crore, up 13.6 per cent from ₹4,895 crore in the same period last year.
Nilesh Gupta, Managing Director, Lupin, said, the last quarter and the year ended on a “strong note”. The financial year ended March 2025 “was led by strong growth in sales and profitability driven by in-line and new products, and consistent improvement in operating margins backed by strong commercial momentum and operational efficiencies,” he said, optimistic on carrying this momentum in the present year as well.
Lupin’s PAT for the financial year ended March 31, 2025, stood at ₹3,306 crore, up nearly 71 per cent from last year’s ₹1,935 crore. Sales for the year stood at 22,192 crore, up 13 per cent from ₹19,656 crore, last year. The company’s board has also recommended a dividend of 600 percent, a note form the company said.
Lupin’s North America branch clocked revenues of ₹8,395 crore in FY25, up 15.9 per cent (₹7,246 crore in FY24), accounting for 38 per cent of Lupin’s global sales. For the quarter under review (Q4 FY25), its sales were ₹2,261 crore, up 19 per cent (₹1,900 crore in Q4 FY24), accounting for 41 per cent of Lupin’s global sales.
The company received seven abbreviated new drug approvals and from USFDA, and launched two products in the region during the quarter.
Lupin has 138 generic products in the US and continues to be the third largest pharmaceutical player in both the US generic market and the US market by prescriptions, it said.
How it fared in India
The company’s India formulation (finished form of medicine) sales for FY25 stood at ₹7,577 crore, up 13.8 per cent over FY24, accounting for 34 per cent of Lupin’s global sales. Fourth quarter sales for the period under review stood at ₹1,711 crore, up 6.9 per cent compared to last year, accounting for 31 percent of Lupin’s global sales.
Other developed markets sales for FY25 stood at ₹2,507 crore, up 23.4 per cent over last year; accounting for 11 per cent of Lupin’s global sales. Emerging markets sales for FY25 stood at ₹2,535 crore, up 6.8 per cent compared to FY24 and accounting for 11 per cent of Lupin’s global sales.
The company’s global Active Pharmaceutical Ingredient sales stood at ₹1,177 crore for FY25, up 3.1 per cent from last year, accounting for 5 per cent of Lupin’s global sales. Its R&D investment stood at ₹1,767 crore or 8 per cent of sales for FY25, compared to ₹1,526 crore (7.8 per cent of sales) in FY24.
More Like This
Published on May 15, 2025
